-- Scott Roberts
WEDNESDAY, March 7 (HealthDay News) -- Sufaxin (lucinacant) has
been approved by the U.S. Food and Drug Administration to prevent
respiratory distress syndrome, a serious lung condition that
affects infants born prematurely.
Premature birth is defined as being born before 37 weeks'
gestation. The lungs of infants born this early can't produce
surfactant, a liquid that coats the lungs and prevents them from
collapsing. Most babies with respiratory distress syndrome show
signs of breathing problems within the first hours after birth, the
FDA said in a news release.
Sufaxin, the fifth FDA-approved drug for respiratory distress
syndrome, was evaluated in clinical studies involving nearly 1,300
premature infants. Most side effects involved the breathing tube
used to administer the drug. Adverse reactions included tube reflux
or obstruction, skin paleness and the need for dose
Sufaxin is produced by Discovery Laboratories, of Warrington,
The U.S. National Library of Medicine has more about
respiratory distress syndrome.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.